Interpace Diagnostics Group Reports Full Year and Fourth Quarter 2018 Financial Results

NEXT STORY
DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
PREV STORY
Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Actions Against Chembio Diagnostics, Inc. (CEMI) and August 17 Deadline

author_avatar
NASDAQ Market News

Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema

-  In the pivotal study, patients taking TAKHZYRO 300 mg every 2 weeks had an ...

author_avatar
NASDAQ Market News

Radius Health Initiates Phase 1 Clinical Trial of RAD140 for the Treatment of Hormone Receptor Positive Breast Cancer

WALTHAM, Mass., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today ...

author_avatar
NASDAQ Market News